EUVIMEDEUVIMED entdecken
Crossref

Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study

Qing Yan, Jianwen Liu, Xianming Long, Chenmin Wu, Diantian Lin, Yanfang Wu, Fei Gao, Li Zhang, Ning Chen

Clinical Rheumatology · 2024-10 · 43 (10) · 3139-3145

DOI: 10.1007/s10067-024-07103-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, online erschienen am 13.08.2024. Verfasst von Qing Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou Universi…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Pyrimidines, Piperidines, Arthritis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Joint Funds for the Innovation of Science and Technology, Fujian province, National Natural Science Foundation of China, Fujian Provincial Health Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To estimate the effectiveness and safety of tofacitinib in treating systemic lupus erythematosus (SLE) patients with arthritis. METHODS: This research was a retrospective cohort study that focused on SLE patients who had arthritis and were treated with tofacitinib at the Department of Rheumatology and Immunology from January 2020 to January 2022. Clinical outcomes, disease activity, immunological parameters, and adverse events were systematically evaluated pre- and post-treatment at 4, 12, and 24 weeks. RESULTS: Twenty-two patients were analyzed. At the 4-week mark, 5 (22.7%) patients were partially relieved, and 17 (77.3%) unalleviated. By the 12-week assessment, CR off corticosteroids was observed in four patients (18.2%), and CR on corticosteroids was seen in six patients (27.3%), with an additional six (27.3%) maintaining partial remission. At 24 weeks after treatment, three patients (13.6%) achieved CR off corticosteroids, ten patients (45.5%) achieved CR on corticosteroids, and all patients received remission. Compared to before treatment, The SLEDAI and PGA scores significantly improved. The level of C3 was increased significantly, and the absolute CD3+ T cell count, the 28-tender and the 28-swollen joint count, and the levels of serum IL-6 were significantly decreased at 24 weeks after treatment. CONCLUSION: Tofacitinib demonstrates significant therapeutic potential in SLE patients with arthritis, with a safety profile, and the therapeutic mechanism of tofacitinib may be related to reducing IL-6 expression and inhibiting T cell activation. Key Points • Tofacitinib demonstrates significant therapeutic potential in SLE patients with arthritis • The therapeutic mechanism of tofacitinib may be related to reducing IL-6 expression and inhibiting T cell activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicPyrimidinesPiperidinesArthritisHumansRetrospective StudiesFemaleMaleAdultMiddle AgedTreatment OutcomeProtein Kinase InhibitorsRemission InductionYoung Adult

Stichwörter der Autor:innen

ArthritisSystemic lupus erythematosusTofacitinib

Substanzen

tofacitinibPyrimidinesPiperidinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
  • Department of Rheumatology and Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Department of Nephrology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China. lilydoctor9902@163.com.
  • Department of Infectious Diseases, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China. puma200003@163.com.

Förderung

  • Joint Funds for the Innovation of Science and Technology, Fujian province
  • National Natural Science Foundation of China
  • Fujian Provincial Health Technology Project
  • Natural Science Foundation of Fujian
  • the First Affiliated Hospital of Soochow University BOXI Clinical Research Project

Zitieren

APA

Yan, Q., Liu, J., Long, X., Wu, C., Lin, D., Wu, Y., Gao, F., Zhang, L., & Chen, N. (2024). Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study. Clinical Rheumatology, 43(10), 3139-3145. https://doi.org/10.1007/s10067-024-07103-2

Vancouver

Yan Q, Liu J, Long X, Wu C, Lin D, Wu Y, et al. Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study. Clinical Rheumatology. 2024;43(10):3139-3145. doi:10.1007/s10067-024-07103-2

BibTeX
@article{Yan2024,
  author = {Yan, Qing and Liu, Jianwen and Long, Xianming and Wu, Chenmin and Lin, Diantian and Wu, Yanfang and Gao, Fei and Zhang, Li and Chen, Ning},
  title = {Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study},
  journal = {Clinical Rheumatology},
  year = {2024},
  volume = {43},
  number = {10},
  pages = {3139--3145},
  doi = {10.1007/s10067-024-07103-2}
}
Kostenlos starten →